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Purpose. Delivery of apoptosis-inducing compounds to hepatic stellate cells (HSC) may be an effective
strategy to reverse liver fibrosis. The aim of this study was therefore to examine the selective targeting of
the apoptosis-inducing drug 15-deoxy-D12,14-prostaglandin J2 (15dPGJ2) with two different HSC-
carriers: human serum albumin modified with the sugar mannose-6-phosphate (M6PHSA) or albumin
modified with PDGF-receptor recognizing peptides (pPBHSA).
Methods and Results. After chemical conjugation of 15dPGJ2 to the carriers, the constructs displayed
pharmacological activity and specific receptor-mediated binding to HSC in vitro. Unlike 15dPGJ2-
pPBHSA, the cellular binding of 15dPGJ2-M6PHSA was reduced by a scavenger receptor antagonist. In
vivo, both conjugates rapidly accumulated in fibrotic livers. Intrahepatic analysis revealed that 15dPGJ2-
M6PHSA mainly accumulated in HSC, and to a lesser extent in Kupffer cells. 15dPGJ2-pPBHSA also
predominantly accumulated in HSC with additional uptake in hepatocytes. Assessment of target
receptors in human cirrhotic livers revealed that M6P/IGFII-receptor expression was present in fibrotic
areas. PDGF-b receptor expression was abundantly expressed on human fibroblasts.
Conclusions. These studies show that 15dPGJ2 coupled to either M6PHSA or pPBHSA is specifically
taken up by HSC and is highly effective within these cells. Both carriers differ with respect to receptor
specificity, leading to differences in intrahepatic distribution. Nevertheless, both carriers can be used to
deliver the apoptosis-inducing drug 15dPGJ2 to HSC in vivo.
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INTRODUCTION
Liver fibrosis may occur as a response to chronic liver
injury and may lead to cirrhosis. HSC play a pivotal role in
this fibrogenic process, because this cell starts to proliferate
and accumulate within the injured liver. During this activa-
tion process, increased amounts of collagen and other
extracellular matrix compounds and inhibitors with matrix
degrading activity are produced by these HSC, thereby
strongly affecting the liver architecture and eventually liver
function (1,2). Up till now, no pharmaceutical intervention is
available to treat this fibrotic disease (3). The application of
antifibrotic drugs has not been successful, partly because
these drugs do not accumulate in the target cells in the
diseased liver or cause side effects elsewhere in the body.
Alteration of the pharmacokinetic characteristics of the drug
by means of drug targeting may represent a promising
approach in the development of an effective antifibrotic drug.
In recent years, different HSC-selective carrier systems
have become available (4Y6). One system uses the sugar
mannose-6-phosphate which is coupled to the protein human
serum albumin to form M6P28HSA. This carrier binds to
mannose-6-phosphate/insulin-like growth factor-II (M6P/
IGFII) receptors (4,7Y10). The expression of these M6P/
IGFII receptors increases as a result of HSC activation
during liver fibrosis (11) enabling selective accumulation of
M6PHSA in HSC of fibrotic rats (4).
In other delivery systems for HSC, the homing devices
are cyclic receptor-recognizing peptides (5,6). The carrier
homing to the PDGF-b receptor (pPBHSA) may be quite
relevant, since PDGF-BB is the major cytokine involved in
the proliferation of HSC during the fibrotic process, and the
PDGF-" receptor is highly upregulated on activated HSC
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ABBREVIATIONS: BDL, bile duct ligation; FCS, fetal calf serum;
HSA, Human Serum Albumin; HSC, hepatic stellate cells; M6P/
IGFII receptor, Mannose-6-Phosphate/Insulin-like Growth Factor-II
receptor; M6PHSA, human serum albumin modified with the sugar
mannose-6-phosphate; PDGF-b receptor, platelet derived growth
factor beta receptor; pPBHSA, human serum albumin modified with
PDGF-receptor recognizing peptides; 15dPGJ2, 15d-prostaglandin J2.(12,13). The carrier pPBHSA competitively inhibited the
binding of PDGF-BB to its receptor, and in vivo preferen-
tially homed to the HSC in fibrotic rat livers with minor
uptake in hepatocytes (5). In vivo, uptake was associated
with disease-induced expression of the PDGF receptor in
liver and kidney.
In experimental liver fibrosis, resolution of the disease
was found to be accompanied by loss of HSC via spontaneous
induction of apoptosis in these cells (14,15). Therefore,
induction of apoptosis in HSC might represent an attractive
approach to reverse this liver disease. In this respect,
15dPGJ2 is interesting, because it was shown that this
prostaglandin induced apoptosis of human hepatic myofibro-
blasts (16). In addition, sub-apoptotic concentrations of
15dPGJ2 significantly inhibited the expression of interstitial
collagens as well as its proliferation in human hepatic
myofibroblasts in vitro (17,18). 15dPGJ2 was also found in
vivo at sites of inflammation during the resolution phase of
the disease, suggesting that it might function as a negative
feedback regulator of the inflammatory process (19).
However, generally the pharmacokinetic properties of
prostaglandins limit their therapeutic use. Prostaglandins are
locally acting mediators that are rapidly metabolized by the
lung (20) or in plasma (21) and excreted from the body via
the kidneys resulting in a very short half life (22). For
example, prostaglandin E2 (dinoprostone) has a plasma half-
life (t1/2) of less than 1 min and prostaglandin I2 (epoproste-
nol) has a t1/2 of 2Y3 min (23). The t1/2 of 15dPGJ2 is not
known. In addition, the high protein binding of prostaglan-
dins in serum (24) might prevent 15dPGJ2 to effectively
reach the essential cells within the liver after systemic
administration. In line with this, in vitro studies demonstrated
that pharmacological effects of 15dPGJ2 were abolished in
the presence of serum (16). Specific delivery of prostaglan-
dins to HSC might overcome these problems.
The aim of this study was therefore to chemically couple
15dPGJ2 to two different HSC-selective drug carriers, i.e.,
M6PHSA and pPBHSA, and to compare their effectiveness
by studying the uptake and pharmacological effects within
the target cells.
MATERIAL AND METHODS
Materials
HSA was purchased from the Central Laboratory of
Blood Transfusion Services (Sanquin Blood Supplies,
Amsterdam, The Netherlands). 15dPGJ2 was purchased from
ITK Diagnostics (Uithoorn, The Netherlands). All other
chemicals used were of analytical grade.
Animals
Wistar rats (male, outbred strain, obtained from Harlan,
Horst, The Netherlands) were housed under standard
laboratory conditions and had free access to food and water.
This study was performed in accordance with ethical
regulations imposed by Dutch legislation.
Synthesis
M6PHSA. HSA was modified with mannose-6-
phosphate groups as described (4). The monomeric fraction
was separated from the dimeric and polymeric fraction by
size-exclusion chromatography on a HiLoad 16/60 Superdex
200 column (GE Healthcare, Uppsala, Sweden) in an FPLC
system. The monomeric protein was characterized for
protein, sugar, and phosphate content.
pPBHSA. The cyclic peptide C*SRNLIDC* was pre-
pared by Ansynth Service BV (Roosendaal, The Nether-
lands) and covalently coupled to HSA as described (5).
Conjugation of 15dPGJ2 to the Albumin Carriers. The
carboxylic acid group of 15dPGJ2 (10 mg; 32 mmol) dissolved
in 150 ml dimethylformamid (DMF)) was activated with 12.5
mg (61 mmol) N,N-dicyclohexylcarbodiimide (DCC, Sigma,
St. Louis, MO, USA), in a ratio 15dPGJ2:DCC=1:2,
dissolved in 80 ml DMF and stirred for 1 h (RT). This
15dPGJ2/DCC solution was subsequently added to 20 mg
(0.25 mmol) M6PHSA or pPBHSA (dissolved in PBS, 4 mg/
ml) in ratio 15dPGJ2:carrier=130:1, and the mixture was
stirred at RT during 16 h. The obtained solutions were
extensively dialyzed (Slide-A-Lyzer 10K, Pierce Biotechnol-
ogy, Rockford, IL, USA) against milliQ water at 4-C for 2
days followed by overnight dialysis against 5 mg/ml HSA
solution to remove all low molecular weight compounds and
unbound 15dPGJ2. The conjugates were lyophilized and
stored at j20-C. The amount of 15dPGJ2 coupled to the
carrier was assessed using the 15dPGJ2 correlate-EIA kit
(Assay Designs, Ann Arbor, Michigan, USA).
Rat Hepatic Stellate Cell Isolation
We isolated primary HSC from livers of rats (T500 g
body weight) using in situ perfusion and subsequent digestion
of the livers with collagenase P, DNAse (both Roche
Diagnostics, Indianapolis, IN, USA) and pronase E (Merck,
Darmstadt, Germany). After separation of the HSC from
other hepatic cells by density-gradient centrifugation, the
HSC were collected on top of a 12% Nycodenz-solution (25).
Subsequently, the cells were cultured in DMEM (Invitrogen,
Carlsbad, CA, USA) supplemented with 10% fetal calf serum
(FCS), and incubated in a 5% CO2 humidified atmosphere at
37-C. Cells cultured for 10 days were used for further
experiments. At this time point, all cells have an activated
phenotype. This was routinely microscopically evaluated and
regularly checked by staining for a-smooth muscle actin using
a monoclonal antibody (clone 1A4, Sigma).
Binding to HSC
To assess the cellular binding of the conjugates as
described (7), 15dPGJ2-M6PHSA and 15dPGJ2-pPBHSA
were radioactively labelled with
125I( 26).
One hundred thousand cells (10 days after isolation)
were grown in a six well-plate and pre-incubated with 1%
bovine serum albumin in DMEM to block non-specific
binding. HSC were then incubated at 37-C with 100,000
cpm of
125I-labelled conjugate in DMEM with 0.2% bovine
serum albumin. In addition, wells were co-incubated with
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(PIA, 10 mg/ml). After 2 h, cells were washed with PBS and
the cell-associated radioactivity was measured on a g-counter
(Riastar, Packard instruments, Palo Alto, USA). These
experiments were performed with cells of three separate
HSC isolations.
Biological Effects on HSC
HSC (day 7 after isolation; 5,000/well) were incubated in
a 96-well plate for 24 h in 200 ml medium with serum, then
washed with serum-free medium and incubated for an
additional 24 h in 200 ml medium with or without 10% FCS.
Subsequently, 15dPGJ2, 15dPGJ2-M6PHSA, M6PHSA,
15dPGJ2-pPBHSA or pPBHSA were added in increasing
concentrations and the cells were incubated with or without
10% FCS for another 18 h. Alamar blue (20 ml, Serotec,
Oxford, UK) was added and the cells were incubated for an
additional 24 h (i.e., final analysis of HSC at day 10 after
isolation). The conversion of Alamar blue by the metabolic
activity of the cells reflects the number of cells (i.e., net result
of proliferation and apoptosis) present in each well. The
Alamar blue conversion was measured with a fluorimeter
(27). These experiments were performed with cells of three
separate HSC isolations.
Animal Model of Liver Fibrosis
To induce liver fibrosis, rats (220Y240 g) were subjected
to bile duct ligation (BDL) under isoflurane/O2/N2O anes-
thesia. The rats were used for further experiments at 10 days
after ligation, when HSC are activated and excess of
extracellular matrix deposits are clearly present (portal
expansion with occasional portal-to-portal bridging).
Organ Distribution
BDL rats were injected intravenously, in the penile vein,
with a tracer dose of
125I-HSA,
125IY15dPGJ2-M6PHSA or
125IY15dPGJ2-pPBHSA (1.10
6 cpm per rat, n=3/group)
under anaesthesia. Fifteen minutes after injection, the
animals were sacrificed, blood was obtained by heart
puncture and organs were removed. The radioactivity in
each organ was measured with a g-counter (Packard
instruments). The total radioactivity measured in the total
o r g a nw a sc o r r e c t e df o rt h eb l o o d - d e r i v e dr a d i o a c t i v i t y
according to standard procedures (6).
Hepatic Localization
Anaesthetized BDL rats were injected intravenously
with 2 mg/kg 15dPGJ2-M6PHSA or 15dPGJ2-pPBHSA
(n=3/group). Fifteen minutes after administration, the rats
were sacrificed and sections of the liver were frozen in
isopentane (j80-C).
Immunohistochemical analysis of acetone-fixed cryostat
sections (4 mm) of the livers was used to localize the carrier.
Therefore, livers were double-stained with a polyclonal
antibody against HSA (MP Biomedicals, Zoetermeer, The
Netherlands) combined with an antibody specific for either
the Kupffer cells (ED2, Serotec), sinusoidal endothelial cells
(RECA1, Serotec) or HSC (Desmin and Glial Fibrillary Acid
Protein (GFAP) simultaneously, both Sigma) (4). The
double-stained sections were quantified by two independent
observers (at least ten microscopical fields at 2010
magnification). The total number of double positive cells
(red staining reflects HSA-positive cells and blue staining
reflects the cell marker) was counted and divided by the total
number of HSA-positive cells (all red staining) in the same
microscopical area. This yielded the relative uptake of the
conjugate by each cell-type.
Localisation of Target Receptors in Human Tissue
Acetone-fixed cryostat sections (4 mm) of human livers
from cirrhotic patients (n=3) and healthy human livers,
obtained from donor livers (n=3), were stained according to
standard immunohistochemical techniques (28). The primary
antibodies used in this study were polyclonal antibodies
directed against the M6P/IGFII-receptor (K-21) and PDGF-b
receptor (958) (both Santa Cruz Biotechnology, CA, USA).
After incubation with two secondary antibodies, amino-ethyl
carbazole (AEC) was used to visualize the staining.
The scientific use of human liver tissue was approved by
the Medical Ethical Committee of the University Medical
Center Groningen (The Netherlands).
Statistics
Results are expressed as TSEM. Statistical analysis was
performed by two tailed Student_s t-test. P values lower than
0.05 were considered statistically significant.
RESULTS
15dPGJ2 was chemically linked via its COOH-group to
the free NH2-group of the lysines as present in M6PHSA and
pPBHSA. Using ELISA techniques to detect 15dPGJ2,w e
assessed the presence of 15dPGJ2 in the lyophilized and
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Fig. 1. Binding of the conjugates
125IY15dPGJ2-M6PHSA (black
bars)a n d
125IY15dPGJ2-pPBHSA (white bars)t oc u l t u r e so f
activated rat HSC. Incubation of
125I-labelled conjugate and excess
amounts of unlabeled M6PHSA, pPBHSA, the scavenger receptor
antagonist polyinosinic acid (PIA), and HSA was performed to assess
receptor-specific uptake of the conjugates by the HSC. The results of
separate experiments with three different HSC isolations are
expressed as the meanTSEM (*=P<0.05 as compared to control
bar). nd=not determined.
568 Hagens et al.purified conjugates, while the carriers alone did not give an
ELISA-signal. We calculated that, respectively, six and eight
molecules 15dPGJ2 were coupled to M6PHSA and pPBHSA.
Subsequently, we confirmed that after conjugation of the
carriers with the lipophilic drug 15dPGJ2, the ability of both
conjugates to bind rat HSC was preserved. Radioactive
studies showed significant binding of both constructs to
HSC in vitro (Fig. 1). To confirm that the cellular internal-
tization of 15dPGJ2 conjugated with M6PHSA or pPBHSA
occurred via two different receptors, i.e., respectively, M6P/
IGFII receptor and PDGFb-receptor, we co-incubated the
radioactive labeled conjugates with excess amounts of
unlabeled M6PHSA or pPBHSA. For these studies, we used
tracer amounts of the radioactive compounds, because tracer
doses are representative for all non-saturated dosages. The
negatively charged molecule polyinosinic acid, a well-known
antagonist of scavenger receptors (29), was included in these
studies because coupling of approximately 33 M6P groups to
albumin significantly increases the net negative charge of the
protein, which implicates that the scavenger receptor might
be involved in the uptake of M6PHSA by HSC.
In Fig. 1 it can be seen that binding of
125IY15dPGJ2-
M6PHSA to HSC was significantly reduced by 81T5%
(P<0.05) after co-incubation with an excess of M6PHSA, a
ligand for the M6P/IGFII receptor. Excess of HSA alone did
not significantly reduce the binding of
125IY15dPGJ2-
M6PHSA to the HSC. Co-incubation with polyinosinic acid
resulted in a reduction of cellular binding by 70T10%
(P<0.05). This indicates that the binding of 15dPGJ2-
M6PHSA to target cells is mediated by M6P/IGFII receptor
and scavenger receptors present on the cell membrane.
The receptor-mediated binding of the other carrier,
125IY15dPGJ2-pPBHSA, was significantly reduced with an
excess of pPBHSA. This protein reduced the binding of
15dPGJ2-pPBHSA to HSC by 66T10% (P<0.05). Neither
co-incubation with HSA nor M6PHSA or polyinosinic acid
reduced the binding of
125IY15dPGJ2-pPBHSA to the HSC,
indicating the specificity of its binding to the cell membrane.
These studies show that the binding and uptake of 15dPGJ2
coupled to the carrier M6PHSA occurs via different cell
membrane receptors than 15dPGJ2 coupled to pPBHSA.
Induction of Apoptosis
We subsequently examined the apoptosis-inducing effect
of 15dPGJ2 in its free form and conjugated to M6PHSA or
pPBHSA by measuring the viability of primary isolated rat
HSC. We also incorporated the influence of serum, since
serum components such as albumin are known factors that
destroy the bioactivity of prostaglandins (24). This aspect is
of course quite relevant in vivo. Addition of native 15dPGJ2
to cells grown without FCS caused a significant and dose-
dependent decline in viability (80% reduction at 20 mM
15dPGJ2). Co-incubation of 15dPGJ2 with 10% FCS complete-
ly abolished the activity of 15dPGJ2 in cell cultures (Fig. 2a).
Subsequently, we examined the effects of both conjugates.
Without FSC, both conjugates induced a dose-dependent
reduction in the viability of HSC starting at a concentration
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Fig. 2. Effect of different 15dPGJ2 forms on the viability of isolated
activated HSC. (a) 15dPGJ2, (b) 15dPGJ2-M6PHSA and the carrier
M6PHSA control, (c) 15dPGJ2-pPBHSA and the carrier pPBHSA
control. The experiments were performed under serum starvation
(black bars) or in the presence of 10% FCS (white bars). Of both
conjugates, the estimated concentration of 15dPGJ2 present in
15dPGJ2-M6PHSA (6 molecules drug/protein) or 15dPGJ2-pPBHSA
(8 molecules drug/protein) is depicted as well as their protein
concentrations. The control cells (incubated with vehicle) are set at
100% viability and control wells without cells are set as 0% viability.
The results are expressed as the meanTSEM (n=3,*=P<0.05).
Fig. 3. In vivo organ distribution of
125I-labeled 15dPGJ2-M6PHSA
(black bars), 15dPGJ2-pPBHSA (striped bars), and HSA (white bars)
at 15 min after intravenous injection of the compounds in rats with
BDL-induced liver fibrosis.
569 Targeting of 15dPGJ2 to HSCof 25 mg/ml 15dPGJ2-M6PHSA (corresponding with 1.9 mM
15dPGJ2) and 10 mg/ml 15dPGJ2-pPBHSA (corresponding
with 1.0 mM 15dPGJ2). It may be derived from Fig. 2a and b
that 15dPGJ2 targeted with pPBHSA is somewhat more
potent than 15dPGJ2 targeted with M6PHSA since lower
concentrations of conjugated drug result in higher efficacy.
However, additional studies are needed to prove this. In the
presence of 10% FCS, both conjugates were still able to
reduce the HSC viability, although the doseYresponse curve
was somewhat shifted to the right (Fig. 2b, 69% reduction at
250 mg/ml 15dPGJ2-M6PHSA; Fig. 2c, 81% reduction at 250
mg/ml 15dPGJ2-pPBHSA). This small shift is most likely due
to a serum effect on cells, i.e., in the presence of serum these
cells are more resistant to apoptotic stimuli. When the
carriers alone (250 mg/ml of M6PHSA or pPBHSA) were
incubated with the HSC cultures no influence on cell viability
in both serum and serum-free conditions were measurable
(Fig. 2b and c).
Body Distribution in Rats with Liver Fibrosis
The organ distribution of HSA, 15dPGJ2-M6PHSA and
15dPGJ2-pPBHSA was studied in BDL rats, 10 days after
induction of the disease (Fig. 3). Fifteen minutes after
intravenous administration, both
125IY15dPGJ2-M6PHSA
and
125IY15dPGJ2-pPBHSA accumulated significantly in the
livers (86 and 63% of the dose, respectively), leaving little
conjugate in the blood (3 and 16%, respectively). Less than
3% of the administered
125IY15dPGJ2-M6PHSA and only 7%
of the
125IY15dPGJ2-pPBHSA dose was taken up in other
organs and tissues. In contrast, organ distribution studies of
125IYHSA in BDL-10d rats revealed that the majority of the
injected dose was present in the blood at 15 min after injection
(Fig. 3). In conclusion, these data indicate a rapid and almost
complete distribution of both conjugates to the fibrotic liver.
To determine the cellular specificity of 15dPGJ2-
M6PHSA and 15dPGJ2-pPBHSA within the diseased livers,
we examined the intrahepatic distribution of the conjugates
in BDL-10d rats with immunohistochemical techniques
(Fig. 4). 15dPGJ2-M6PHSA was clearly taken up by non-
parenchymal cells and co-localization with HSC markers was
found (Fig. 4a). Quantitative evaluation by counting double-
positive cells showed that 64% of the double-positive cells
could be identified as HSC (Table I). The second cell type
that displayed substantial uptake of the M6P-conjugate was
the Kupffer cell (39%). Quantitative evaluation of the cellular
distribution of 15dPGJ2 targeted with the other carrier
pPBHSA revealed that 57% of the double-positive non-
parenchymal cells were identified as HSC (Table I). For this
carrier, the hepatocytes also contributed to the uptake of
15dPGJ2-pPBHSA in the fibrotic liver, but our scoring proce-
dure did not allow good quantification of this diffuse staining.
M6P/IGFII and PDGF-b Receptor Staining in Normal
and Cirrhotic Human Livers
Finally, we examined the expression of the target
receptors for our HSC-specific carriers in histologically
normal and cirrhotic human livers (Fig. 5). Normal liver
sections displayed a parenchymal staining for the M6P/IGFII
receptor. In cirrhotic human livers, M6P/IGFII-receptor
Fig. 4. Immunohistochemical localization of 15dPGJ2-M6PHSA (a)
and 15dPGJ2-pPBHSA (b) in liver of BDL-10d rats, 15 min after
intravenous injection of the constructs. Cell-specific localization was
determined by double staining of the livers with an antibody directed
against HSA (red staining) together with cellular markers to detect
HSC (desmin and GFAP; blue staining). Magnification 200. The
inserts shows co-localization of the modified HSA together with HSC
(arrow; magnification 400). P=portal area.
Table I. Estimation of the Intrahepatic Distribution of 15dPGJ2-
M6PHSA and 15dPGJ2-pPBHSA in BDL-10d Fibrotic Rat Livers 15
min after Intravenous Injection
15dPGJ2-M6PHSA 15dPGJ2-pPBHSA
Hepatic Stellate
Cells (%)
64T55 7 T7
Kupffer Cells (%) 39T32 4 T8
Sinusoidal Endothelial
Cells (%)
7T53 2 T7
Hepatocytes j +
The contribution of each hepatic cell type in the total liver uptake of
the conjugate was determined by counting the number of double-
positive cells (HSA+ and cell marker+) relative to the total number
of conjugate-positive cells in the same microscopical field. Values are
expressed as the percentage double-positive cells T SD.
570 Hagens et al.Fig. 5. Immunohistochemical detection of M6P/IGFII-receptor (a, b and c) and PDGF-" receptor (d, e and f) in healthy human livers (a, d;
magnification 2010) and cirrhotic human livers (b, magnification 1010, C magnification 410). A high magnification (c, f; magnification
400) shows that cells in the fibrous bands are positive for both receptors. An asterix indicates the localization of periseptal hepatocytes, the
arrow head shows ductular cholangiocytes, and the arrow points to (myo)fibroblasts. PV=portal vein, N=cirrhotic nodule.
571 Targeting of 15dPGJ2 to HSCexpression was still present in hepatocytes. However, addi-
tional staining for the receptor was found in cells in the
fibrous bands, which are the areas within the liver character-
ized by excessive collagen deposition. The staining was
predominantly detectable on cholangiocytes, both in cells
lining the bile duct and bile ductular structures (Fig. 5c).
PDGF-b receptor expression in normal human livers was
only found in the portal areas, in which the hepatic artery and
portal vein were stained (Fig. 5d). Sinusoidal endothelial cells
were not stained for the PDGF-receptor. The expression of
the PDGF-b receptor was massively enhanced in cirrhotic
human livers (Fig. 5e), and the receptor staining was mainly
detectable in cells within the fibrous bands (Fig. 5f). Our
observations are in line with the reported enhanced expres-
sion of PDGF-b receptor in activated myofibroblasts which
are located in these areas (13).
DISCUSSION
In this study, we compared two HSC-specific carries for
their ability to deliver 15dPGJ2 to fibrogenic cells in the liver.
The first carrier M6PHSA, which is substituted with sugar
groups as homing devices, binds to the M6P/IGFII receptor
present on activated HSC (4). The second carrier pPBHSA,
which is substituted with cyclic peptide homing devices, can
bind to the PDGF-a ˆ receptor which is strongly increased on
the cell-surface of activated HSC (5).
The interaction with HSC as reported for the individual
carriers(5,7) was preserved after coupling of 15dPGJ2 to these
carriers. The receptor-mediated binding of both 15dPGJ2
conjugates was inhibited by co-incubation with its own carrier,
while no effect of HSA was found. These blocking experi-
ments indicate that binding to these cells is mediated by
specific receptors. In addition, co-incubation with polyinosinic
acid, a known blocker for the scavenger receptor class A (29),
strongly reduced the binding of 15dPGJ2-M6PHSA to the
cells. The involvement of scavenger receptors was anticipated
because these receptors bind negatively charged molecules
and M6P-containing compounds have a net negative charge, as
confirmed with FPLC-monoQ analysis. The expression of a
scavenger receptor class B, CD36, was reported on HSC and a
co-localisation with alpha-smooth muscle actin-positive HSC
in human fibrotic livers was immunohistochemically demon-
strated (30). However, inhibition by polyinosinic acid, as found
in our studies, suggests that not scavenger receptor class B, but
rather class A contributed to the accumulation of M6PHSA
conjugates in the HSC. This scavenger receptor class A has
not yet been described on HSC, but our results together with
the observations presented by Adrian et al.( 31)w a r r a n t
further exploration of these receptors on HSC in rat and
human livers. In contrast, binding of 15dPGJ2-pPBHSA to
cultured HSC was not affected by polyinosinic acid, suggesting
that scavenger receptors are not involved in the binding of
pPBHSA to HSC. Moreover, preincubation with M6PHSA
showed that 15dPGJ2-pPBHSA was not interacting with any
of the binding domains of the M6P-carrier. This shows that
both carries use different entry routes to deliver a drug within
the HSC.
15dPGJ2 was conjugated to the carrier via its carboxylic
acid group (COOH). In contrast to the cyclopentenone ring of
prostaglandins, the carboxylic acid group is not essential for
the biological activity (32,33). In our studies, we showed that
both conjugates were able to effectively reduce the viability of
HSC in vitro. This implicates receptor-mediated endocytosis of
the drug-carrier and intracellular degradation of the constructs
in the lysosomes of the cell. Of note, the chemical amide bond
between the carboxylic acid group of the prostaglandin andthe
lysine moieties within HSA cannot be cleaved by intracellular
proteases as present in the lysosomes with part of the carrier
attached to it. Using the same coupling procedures to couple
naproxen to HSA, it was found that naproxen-lysine was
released within the cell, after degradation of naproxen-HSA
(34). Also, coupling of mycophenolic acid to HSA via this
coupling procedure yielded not the parent compound (35). So,
most likely 15dPGJ2 is also not released as the parent
compound but despite this pharmacological activity is present.
Because of its apoptosis-inducing activities, 15dPGJ2
seems an attractive compound to apply in liver fibrosis
(16Y18). However, the therapeutic use of 15dPGJ2 may be
limited because of high albumin binding (24) and expected
poor pharmacokinetics as most of these lipophilic prosta-
glandins easily cross cell membranes. Also, our studies with
HSC in vitro showed that serum completely blocked the
activities of free 15dPGJ2, while both conjugated forms of
15dPGJ2 were still effective and reduced HSC viability
almost comparable to serum-free conditions. The pharmaco-
kinetic parameters of 15dPGJ2 after iv injection have not
been reported, probably because so far no radioactive
compound is available and HPLC detection is not sensitive
enough. The obstacles as encountered in the therapeutic use
of prostaglandins in vivo may be solved by targeting of the
prostaglandin to the HSC by means of conjugation to HSC-
specific carriers.
With regard to an expected low HSC accumulation of
15dPGJ2 in vivo, we now demonstrate a rather complete
targeting to the fibrotic liver of both 15dPGJ2 conjugated
forms. Respectively, 86 and 63% of the dose of 15dPGJ2-
M6PHSA and 15dPGJ2-pPBHSA was present in the liver
already 15 min after intravenous injection. Previously, we
reported an hepatic accumulation of M6PHSA and pPBHSA
of 59 and 48% of the administered dose, 10 min after iv
injection (4,5). The higher liver accumulation as found in the
present studies for 15dPGJ2 conjugated M6PHSA and
pPBHSA may be caused by the attachment of the lipophilic
compound prostaglandin. We also determined the intra-
hepatic localization of both HSC-targeted forms of 15dPGJ2.
15dPGJ2-M6PHSA predominantly accumulated in the HSC
(64%) and Kupffer cells (39%). The high accumulation of
the M6P-conjugate in Kupffer cells is probably related to the
net negatively charged protein backbone of the construct
which is recognized by scavenger receptors (both class A and
B) on these Kupffer cells (29). The other construct 15dPGJ2-
pPBHSA predominantly co-localizes with HSC and paren-
chymal cells. Hepatocyte uptake was relatively low, reflected
by the diffuse staining and could therefore not be quantified.
It is likely that the pPB-conjugate, as also proposed for the
carrier pPBHSA (5), follows a similar distribution pattern as
the growth factor PDGF-BB, which is taken up by hepato-
cytes after opsonization by !2-macroglobulin (36).
Further studies to assess the effects of 15dPGJ2 in cells
that take up the construct are required. Next to the uptake in
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case of the M6PHSA carrier, Kupffer cells and endothelial
cells take up the product parallel to HSC. If effects are found
within these cells, it will determine the choice of carrier. To
date, no effects of 15dPGJ2 have been reported in KC, EC or
hepatocytes. To assess the effects in all cell types and the net
effect on liver fibrosis, the constructs have to be administered
in therapeutic amounts for a prolonged period of time. This is
part of our future research program.
However, the situation within the human diseased liver
has also to be taken into account and we decided to focus on
this issue first and studied the expression of both receptors in
human cirrhotic livers. We demonstrated expression of the
M6P/IGFII receptors in hepatocytes of healthy livers, but in
human cirrhotic livers an increased expression on fibrogenic
cells was observed compared to normal livers. Expression of
this receptor on fibroblasts in humans has been reported (37),
however no data on hepatic stellate cells or myofibroblasts
exist yet. We did find uptake of M6PHSA constructs in
human myofibroblasts and liver slices in vitro (4), but no
significant staining for M6P/IGFII receptor was found in
these cells in the studied human livers. Maybe a detailed
investigation of M6P/IGFII receptor expression during fibro-
genesis in the human liver at various stages of disease and
with various etiologies should be performed. The expression
of M6P/IGFII receptors in hepatocytes as demonstrated in
human livers was also noted in rats (38), but this hepatocyte
receptor expression did not lead to any uptake of M6PHSA
in this cell type (4,35,39). Only uptake of M6PHSA in non-
parenchymal cells was found, probably the receptor expres-
sion in hepatocytes is mostly intracellularly, i.e., not within
reach of extracellular plasma proteins.
The highly induced expression of the PDGF-b receptor
in human cirrhotic livers as detected by us, correlated with its
localization as reported by Pinzani et al.( 13). The high
expression of in particular the PDGF-b receptor compared to
the expression of the M6P/IGFII receptor makes our carrier
with the PDGF receptor-recognizing peptides, pPBHSA, the
most attractive candidate for application in the human
situation. Subsequent studies to examine the distribution of
the drug carriers in human livers or patients will be necessary
to examine the applicability of the carriers in the human
situation, but at least both target receptors are present.
In summary, the coupling of 15dPGJ2 to the HSC-
specific drug carriers M6PHSA and pPBHSA clearly led to a
rapid and near complete accumulation of the prostaglandin
in the fibrotic liver with significant uptake in HSC. Both
targeted forms of 15dPGJ2 were pharmacologically effective
in vitro, and coupling evidently improved the activity of this
prostaglandin in the presence of serum. In vitro receptor
interactions differed between both targeted constructs, which
led to differences in the hepatocellular distribution in vivo.
Studies on long-term effects and on the applicability in
patients will be necessary to determine which construct is the
most effective during disease. Nevertheless, in both cases, the
HSC is the main target cell and in view of the apoptosis-
inducing activities of this prostaglandin in HSC, these
conjugates may be a valuable tool to attenuate the fibrogenic
process within the liver.
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